Nationwide Case-Control Study Examining the Association between Tamoxifen Use and Alzheimer’s Disease in Aged Women with Breast Cancer in Taiwan

Liao, Kuan‐Fu; Lin, Cheng‐Li; Lai, Shih‐Wei

doi:10.3389/fphar.2017.00612

Cited by 26 publications

(18 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, only subjects whose cumulative duration of zolpidem use was ≥12 months were included. The definition of medication exposure was adapted from previous studies ( Cheng et al, 2017 ; Lai et al, 2017 ; Liao et al, 2017c , d ). Subjects who did not have a prescription for medications studied were classified as never use.…”

Section: Methodsmentioning

confidence: 99%

Zolpidem Administration and Risk of Hepatocellular Carcinoma: A Case-Control Study in Taiwan

2017

Self Cite

View full text Add to dashboard Cite

Background/Objectives: Previous studies showed that zolpidem use could be associated with increased cancer risk, but the role of zolpidem on hepatocellular carcinoma (HCC) risk remains undetermined. The study purpose was to examine the association between HCC risk and zolpidem use in Taiwan.Methods: Using the database from the Taiwan National Health Insurance Program, we designed a case-control study which consisted of 77986 subjects aged 20 years or older with newly diagnosed HCC as the case group, and 77986 subjects without HCC as the control group, from 2000 to 2011. Ever use of zolpidem was defined as a subject who had at least a prescription for zolpidem before the index date. Never use was defined as a subject who did not have a prescription for zolpidem before the index date. The association between HCC risk and zolpidem use was determined by the odds ratio (OR) and 95% confidence interval (CI) in a multivariable logistic regression model.Results: After adjustment for confounding factors, the adjusted OR of HCC was 1.05 (95% CI 0.97, 1.13) for subjects with ever use of zolpidem, compared with never use of zolpidem. The adjusted OR of HCC was 1.01 for subjects with increasing cumulative duration of zolpidem use for every 1 year (95% CI 0.99, 1.03), compared with never use of zolpidem.Conclusion: There is no significant association between HCC risk and zolpidem use. There is no duration-dependent effect of zolpidem use on HCC risk.

show abstract

Section: Methodsmentioning

confidence: 99%

Zolpidem Administration and Risk of Hepatocellular Carcinoma: A Case-Control Study in Taiwan

2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Our study was conducted using a US-based population electronic medical record data set and a substantially larger number of women with breast cancer than previously reported. [14][15][16][17][18][19] Furthermore, we investigated the risk of developing multiple age-associated NDDs that occur sporadically within an aging population. We report the association of individual hormonal modulators and their drug families within the HMT category with the risk of development of age-associated NDDs.…”

Section: Introductionmentioning

confidence: 99%

Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer

et al. 2020

View full text Add to dashboard Cite

IMPORTANCE The association between exposure to hormone-modulating therapy (HMT) as breast cancer treatment and neurodegenerative disease (NDD) is unclear. OBJECTIVE To determine whether HMT exposure is associated with the risk of NDD in women with breast cancer. DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study used the Humana claims data set from January 1, 2007, to March 31, 2017. The Humana data set contains claims from privatepayer and Medicare insurance data sets from across the United States with a population primarily residing in the Southeast. Patient claims records were surveyed for a diagnosis of NDD starting 1 year after breast cancer diagnosis for the duration of enrollment in the claims database. Participants were 57 843 women aged 45 years or older with a diagnosis of breast cancer. Patients were required to be actively enrolled in Humana claims records for 6 months prior to and at least 3 years after the diagnosis of breast cancer. The analyses were conducted between January 1 and 15, 2020. EXPOSURE Hormone-modulating therapy (selective estrogen receptor modulators, estrogen receptor antagonists, and aromatase inhibitors). MAIN OUTCOMES AND MEASURES Patients receiving HMT for breast cancer treatment were identified. Survival analysis was used to determine the association between HMT exposure and diagnosis of NDD. A propensity score approach was used to minimize measured and unmeasured selection bias.

show abstract

“…Notably, the use of estrogen receptor antagonists (i.e., tamoxifen) are associated with increased Parkinson's disease risk in women [136][137][138]. However, the role of estrogen receptor antagonists in Alzheimer's disease risk in women is less clear [139][140][141][142][143]. No studies have examined the impact of estrogen receptor antagonists on CNS conditions in men.…”

Section: Discussionmentioning

confidence: 99%

Neuroprotective and neurotoxic outcomes of androgens and estrogens in an oxidative stress environment

et al. 2020

View full text Add to dashboard Cite

Background: The role of sex hormones on cellular function is unclear. Studies show androgens and estrogens are protective in the CNS, whereas other studies found no effects or damaging effects. Furthermore, sex differences have been observed in multiple oxidative stress-associated CNS disorders, such as Alzheimer's disease, depression, and Parkinson's disease. The goal of this study is to examine the relationship between sex hormones (i.e., androgens and estrogens) and oxidative stress on cell viability. Methods: N27 and PC12 neuronal and C6 glial phenotypic cell lines were used. N27 cells are female rat derived, whereas PC12 cells and C6 cells are male rat derived. These cells express estrogen receptors and the membraneassociated androgen receptor variant, AR45, but not the full-length androgen receptor. N27, PC12, and C6 cells were exposed to sex hormones either before or after an oxidative stressor to examine neuroprotective and neurotoxic properties, respectively. Estrogen receptor and androgen receptor inhibitors were used to determine the mechanisms mediating hormone-oxidative stress interactions on cell viability. Since the presence of AR45 in the human brain tissue was unknown, we examined the postmortem brain tissue from men and women for AR45 protein expression. Results: Neither androgens nor estrogens were protective against subsequent oxidative stress insults in glial cells. However, these hormones exhibited neuroprotective properties in neuronal N27 and PC12 cells via the estrogen receptor. Interestingly, a window of opportunity exists for sex hormone neuroprotection, wherein temporary hormone deprivation blocked neuroprotection by sex hormones. However, if sex hormones are applied following an oxidative stressor, they exacerbated oxidative stress-induced cell loss in neuronal and glial cells.

show abstract

Nationwide Case-Control Study Examining the Association between Tamoxifen Use and Alzheimer’s Disease in Aged Women with Breast Cancer in Taiwan

Cited by 26 publications

References 34 publications

Zolpidem Administration and Risk of Hepatocellular Carcinoma: A Case-Control Study in Taiwan

Zolpidem Administration and Risk of Hepatocellular Carcinoma: A Case-Control Study in Taiwan

Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer

Neuroprotective and neurotoxic outcomes of androgens and estrogens in an oxidative stress environment

Contact Info

Product

Resources

About